Clinical Trial Search

Primary: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-Years…

Primary: Change in Left Ventricular End Systolic Volume (ml) — -4.4; -1.2; -3.8 mL

Primary: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization — 33.6; 37.8 Parts w/ event per 100 part-yrs at risk…

Primary: Change From Baseline to Week 12 in Exercise Capacity as Measured by the 6-Minutes-Walking-Test (6MWT) Distance — 18.0; 13.5 Meter (m) — p=0.4236

Primary: Time to Cardiovascular Death or First Heart Failure Event — 39.1; 37.0 percentage of participants — p=0.0252

Primary: Time to the First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF) — 21.00; 15.77 Patients with events/ 100 pt-yrs…

Primary: Change in Left Ventricular End-diastolic Volume — -6; -4 mL

Primary: Percent Change in Serum Creatinine at 72 Hours. — 4; 11; 5; 20 percent change in serum creatinine

Primary: Treatment Tolerability: Number of Participants Without Discontinuation of Study Intervention (Incl. Max. 1 Day Interruption) and Without Moderate to Severe Symptomatic…

Primary: Measured Adherence to GDMT by Pill Count — 74.6; 83.3 adherence ratio expressed in %

Primary: Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12 — 0.8218; 0.9828 Ratio — p=<0.0001

Primary: All-cause Death, Heart Failure-related Re-hospitalizations, and a Composite Outcome of Both Death and Heart Failure-related Re-hospitalizations — 36; 15; 41; 18…

Primary: Hierarchical Composite Endpoint Composed of Time to Cardiovascular (CV) Death, Time to First Heart Failure (HF) Hospitalization, and Relative Change in NT-proBNP From…

Primary: Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and…

Primary: Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure. — 512; 610 Participants — p=0.0008

Primary: Percentage of Patients With LVEF Recovery at Day 90 and 180 — 222; 0; 0; 0 Participants

Primary: Change From Baseline in Log-Transformed N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP) to Week 12 — -0.28; -0.265; -0.32; -0.353 log-transformed picograms per…

Primary: Change in Plasma N-terminal Proatrial Natriuretic Peptide (NT proANP) — 47.4; 46.4 pg/mL

Primary: Change in Pulmonary Capillary Wedge Pressure During Exercise — -1; -4 millimeters of mercury — p=0.002

Primary: Percentage That Had Increase in Classes of Guideline Directed Medical Therapy — 66.2; 13.1 percentage of patients

Primary: Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure — 889; 828 Participants…

Primary: Absolute Change From Baseline in Left Ventricular Ejection Fraction (LVEF) (%) at Week 20 Measured by Echocardiography — -2.19; 2.59; -3.01; 0.13 Percentage of LVEF…

Primary: Exercise Pulmonary Capillary Wedge Pressure (PCWP) — 19.0; 28.0 mm Hg — p=0.0003

Primary: Exercise Tolerance Assessed by 6 Minute Walking Test — 474.8; 435.7; 453.1 meters

Primary: Number of Participants Who Had CEC (Clinical Endpoint Committee) Confirmed Composite Endpoints — 30; 28; 0; 0 Participants

Primary: Cumulative Number of Primary Composite Events of Cardiovascular (CV) Death and Total (First and Recurrent) HF Hospitalizations. — 894; 1009; 690; 797 Events — p=0.0587

Primary: Percent of Participants Who Experienced an Initiation or Intensification of Their Guideline-Directed Medical Therapy (GDMT) — 29.7; 49.0 percentage of participants

Primary: Effect of Dapagliflozin, as Compared With Placebo, on Heart Failure Related Health Status Using the Kansas City Cardiomyopathy Questionnaire Clinical Summary Summary…

Primary: Coronary Flow Reserve — 2.64; 2.65; 2.06 ratio

Primary: Change From Baseline to Week 12 in Exercise Capacity as Measured by the Distance Walked in 6 Minutes in Standardised Conditions (6MWTD) — 5.0; 10.0 Meter (m) — p=0.3660